Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Concurrent chemotherapy and radiation therapy (chemoRT) has become the standard of care for
treatment of many patients with advanced head and neck squamous cell carcinoma (HNSCC),
though many clinical questions remain. Prior experience has revealed locoregional control
(LRC), disease free survival (DFS) and overall survival (OS) at 3 years exceeding 80% after
treatment with the use of hyperfractionated intensity modulated radiation therapy (IMRT) and
concurrent weekly cisplatin chemotherapy for patients with locally advanced HNSCC. This
multi-institutional phase II ZCC00204 trial resulted in an acceptable quality of life (QOL)
and toxicity profile. The current trial is an attempt to maintain high LRC, while further
minimizing both acute and chronic toxicities, and maximizing QOL.
Phase:
Phase 2
Details
Lead Sponsor:
Coastal Carolina Radiation Oncology
Collaborators:
National Cancer Institute (NCI) New Hanover Regional Medical Center